Abstract #0373
PSMA-Specific Theranostic Nanoplexes for Combination Gene and Prodrug Therapy of Prostate Cancer
Zhihang Chen 1 , Marie-France Penet 1 , Balaji Krishnamachary 1 , Sangeeta Ray Banerjeee 1 , Martin G. Pomper 1 , and Zaver M. Bhujwalla 1
1
Russell H. Morgan Department of Radiology
and Radiological Science, Johns Hopkins University
School of Medicine, Baltimore, MD, United States
Prostate cancer (PCa) is the second leading cause of
death from cancer in men in the U.S., and there is a
compelling need for the development of effective
treatments for metastatic PCa. Prostate-specific
membrane antigen (PSMA) is a membrane protein that has
abundant and restricted expression on the surface of
castrate-resistant PCa, and is therefore a promising
target for combined diagnosis and therapy of metastatic
PCa. Here we achieved PSMA-specific delivery of a tumor
necrosis factor-related apoptosis-inducing ligand
(TRAIL) cDNA gene and a prodrug enzyme bacterial
cytosine deaminase (bCD) using a nanoplex based
polyethyleneimine (PEI) platform.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
